Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-12-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于长春百克生物科技股份公司首次公开发行股票部分募投项目变更用途的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed special verification opinion from CITIC Securities regarding the change in use of part of the proceeds from the initial public offering (IPO) of Changchun Baike Biotechnology Co., Ltd. It references regulatory guidelines related to the management and use of raised funds, details the original and new investment projects, and includes opinions from independent directors, the supervisory board, and the sponsor institution. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a regulatory compliance and verification report related to the use of IPO proceeds, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Audit Report. The document length (6356 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or a financial report.
2023-12-13 Chinese
长春百克生物科技股份公司股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Shareholders' Meeting Rules" of Changchun Baike Biotechnology Co., Ltd. It extensively details the rules, procedures, rights, and obligations related to the company's shareholders' meetings, including the convening, proposal submission, voting procedures, and legal compliance. It does not contain financial statements, audit results, or earnings data. Instead, it is a governance document outlining the internal rules and procedures for shareholder meetings. This matches the description of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2023-12-13 Chinese
长春百克生物科技股份公司关于修订《公司章程》及修订公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding revisions to the company's Articles of Association and certain governance systems. It includes specific changes to the company's bylaws, board structure, committee responsibilities, and governance practices. The content focuses on corporate governance rules and internal company regulations rather than financial results, audit opinions, or shareholder meeting results. There is no indication that this is a full annual report, audit report, earnings release, or any other financial report. The document is not a brief announcement but a substantive governance-related disclosure. Therefore, the most appropriate classification is Governance Information (CGR).
2023-12-13 Chinese
长春百克生物科技股份公司第五届董事会独立董事关于第五届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Changchun Baike Biotechnology Co., Ltd. regarding a board meeting agenda item about changing the use of some raised funds. It references compliance with company law, stock exchange listing rules, and company articles. The document is a formal opinion on a board matter, not a full report or financial statement. It does not contain financial data or results, nor is it an announcement of a report publication. It is related to board/management information, specifically the independent directors' opinion on a board resolution. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on governance and board opinions, fitting MANG rather than other categories.
2023-12-13 Chinese
长春百克生物科技股份公司信息披露管理制度
Governance Information Classification · 95% confidence The document is a detailed information disclosure management system of a company, outlining principles, responsibilities, procedures, and requirements for information disclosure. It references regulatory bodies such as the China Securities Regulatory Commission and Shanghai Stock Exchange rules. The content focuses on the company's internal rules and governance regarding information disclosure, including periodic reports, temporary reports, and major event disclosures. It does not contain actual financial statements or financial results but rather the governance framework and procedural guidelines for disclosures. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-13 Chinese
长春百克生物科技股份公司关于部分募集资金投资项目变更用途的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Changchun Baike Biotechnology Co., Ltd. regarding a change in the use of part of the funds raised from their initial public offering (IPO). It details the change in the investment project funded by the raised capital, including the project name, investment amounts, and expected completion dates. The document includes opinions from the board of directors, supervisory board, and the sponsoring institution, and states that the change will be submitted to the shareholders' meeting for approval. The content focuses on the use of raised funds and project changes rather than presenting financial statements or results. It is a regulatory announcement about the change in use of capital raised, not a full financial report or earnings release. Therefore, it fits best into the category of Capital/Financing Update (CAP).
2023-12-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.